Haematologica EWOG-MDS website
HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Parody, R
Right arrow Articles by Fontcuberta, J
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Parody, R
Right arrow Articles by Fontcuberta, J
Haematologica, Vol 88, Issue 11, ECR32-ECR32
Copyright © 2003 by Ferrata Storti Foundation

Case Reports

Fondaparinux (ARIXTRA) as an alternative anti-thrombotic prophylaxis when there is hypersensitivity to low molecular weight and unfractionated heparins

R Parody, A Oliver, JC Souto, and J Fontcuberta

Unitat d'Hemostasia i Trombosi. Hospital de la Santa Creu i Sant Pau. Barcelona, Spain.

During the last decade, new anticoagulant drugs with anti-factor-Xa properties have been described (1, 2). Among them is fondaparinux that has been licensed recently. It is a pentasaccharide mimicking the site where heparin binds to antithrombin III (1). This new drug has produced very promising clinical results in the prophylaxis of venous thrombosis after orthopedic surgery (3). Here we report two different clinical situations in which fondaparinux has yielded a successful outcome: first, a patient with repeated cutaneus reaction to several different low molecular weight heparins (LMWH), and second, a patient with severe heparin-induced thrombocytopenia (HIT). We decided to use fondaparinux in both cases since it is commercially available in Spain and mostly because the absence of in vitro cross-reaction with heparins, as discussed later.


This article has been cited by other articles:


Home page
 ChestHome page
J. Hirsh, K. A. Bauer, M. B. Donati, M. Gould, M. M. Samama, and J. I. Weitz
Parenteral Anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Chest, June 1, 2008; 133(6_suppl): 141S - 159S.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
L. E Efird and D. R Kockler
Fondaparinux for Thromboembolic Treatment and Prophylaxis of Heparin-Induced Thrombocytopenia
Ann. Pharmacother., July 1, 2006; 40(7): 1383 - 1387.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
T. E. Warkentin, R. J. Cook, V. J. Marder, J.-A. I. Sheppard, J. C. Moore, B. I. Eriksson, A. Greinacher, and J. G. Kelton
Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin
Blood, December 1, 2005; 106(12): 3791 - 3796.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
M. Haase, R. Bellomo, J. Rocktaeschel, S. Ziemer, H. Kiesewetter, S. Morgera, and H.-H. Neumayer
Use of fondaparinux (ARIXTRA(R)) in a dialysis patient with symptomatic heparin-induced thrombocytopaenia type II
Nephrol. Dial. Transplant., February 1, 2005; 20(2): 444 - 446.
[Full Text] [PDF]

Home page
 BloodHome page
P. Savi, B. H. Chong, A. Greinacher, Y. Gruel, J. G. Kelton, T. E. Warkentin, P. Eichler, D. Meuleman, M. Petitou, J.-P. Herault, et al.
Effect of fondaparinux on platelet activation in the presence of heparin-dependent antibodies: a blinded comparative multicenter study with unfractionated heparin
Blood, January 1, 2005; 105(1): 139 - 144.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
Copyright © 2003 by the Ferrata Storti Foundation.